EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.
Journal Title
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
EUR J CLIN PHARMACOL
ISSN / eISSN
0031-6970 / 1432-1041
Aims and Scope
The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.
Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor.
Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves
-a compound that is interesting and new in some basic or fundamental way, or
-methods that are original in some basic sense, or
-a highly unexpected outcome, or
-conclusions that are scientifically novel in some basic or fundamental sense.
Subject Area
PHARMACOLOGY & PHARMACY
CiteScore
5.00
View Trend
CiteScore Ranking
| Category | Quartile | Rank |
|---|---|---|
| Medicine - Pharmacology (medical) | Q2 | #97/260 |
| Medicine - Pharmacology | Q2 | #142/301 |
Web of Science Core Collection
| Science Citation Index Expanded (SCIE) | Social Sciences Citation Index (SSCI) |
|---|---|
| Indexed | - |
| Category (Journal Citation Reports 2023) | Quartile |
|---|---|
| PHARMACOLOGY & PHARMACY - SCIE | Q3 |
H-index
99
Country/Area of Publication
GERMANY
Publisher
Springer Berlin Heidelberg
Publication Frequency
Monthly
Year Publication Started
1968
Annual Article Volume
162
Open Access
NO
Contact
SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013
Verified Reviews
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now